| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Z-Arg-AMC HCl targets trypsin, cathepsin B, and cathepsin H, which are proteases that cleave peptide bonds after arginine residues. The compound is a substrate for these enzymes; it contains an arginine residue that is recognized by the active site of the proteases. Upon enzymatic cleavage, the AMC fluorophore is released and its fluorescence (Ex/Em=355/460 nm) can be quantified. This property makes it a valuable tool for measuring protease activity.
|
|---|---|
| ln Vitro |
In vitro, Z-Arg-AMC HCl is used as a fluorogenic substrate in enzymatic assays to measure protease activity. The compound is incubated with the enzyme, and the released AMC is detected by fluorescence spectroscopy. It can be used to study enzyme kinetics, screen for inhibitors, and monitor protease-related pathways involved in inflammation, apoptosis, and cancer progression.
|
| ln Vivo |
Z-Arg-AMC HCl does not have in vivo biological activity as a pharmacological agent. It is a substrate used in biochemical assays and is not intended for administration to animals or humans as a therapeutic. Its value is as a research tool for studying protease activity.
|
| Enzyme Assay |
In vitro enzymatic assays using Z-Arg-AMC HCl measure protease activity. The substrate is incubated with the enzyme (trypsin, cathepsin B, or cathepsin H) in a suitable buffer. The reaction is monitored by measuring the increase in fluorescence (Ex/Em=355/460 nm) over time. These assays are used to study enzyme kinetics and to screen for protease inhibitors.
|
| Cell Assay |
Cell-based assays for Z-Arg-AMC HCl are limited, as the compound is primarily used as a substrate in cell-free enzymatic assays. It may be used in cell culture supernatants or lysates to measure protease activity released from cells. However, specific protocols are not extensively documented.
|
| Animal Protocol |
In vivo animal experiments are not applicable to Z-Arg-AMC HCl as it is a research reagent, not a therapeutic agent. The compound is not intended for administration to animals. Its value is as a biochemical tool for in vitro studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Z-Arg-AMC HCl as it is a research reagent, not a therapeutic agent. The compound has a molecular formula of C24H28ClN5O5 and a molecular weight of 502.0 g/mol. Storage: -20°C, protected from light. Specific solubility data are not available.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for Z-Arg-AMC HCl are limited. As a biochemical reagent, it should be handled with appropriate safety precautions. The compound is for research use only and is not for human therapeutic use. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
Z-Arg-AMC HCl has CAS number 70375-22-3, molecular formula C24H28ClN5O5, and molecular weight 502.0 g/mol. Synonyms: Z-(L-Arg)-AMC hydrochloride. It is a fluorogenic substrate for trypsin, cathepsin B, and cathepsin H. Ex/Em=355/460 nm. Not for human use; for research purposes only.
|
| Molecular Formula |
C24H27N5O5.HCL
|
|---|---|
| Molecular Weight |
501.96262
|
| Exact Mass |
501.178
|
| CAS # |
70375-22-3
|
| PubChem CID |
16219161
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
793ºC at 760 mmHg
|
| Melting Point |
204-205ºC
|
| Flash Point |
433.4ºC
|
| LogP |
5.055
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
789
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3.Cl
|
| InChi Key |
JYWCRDUTYUBXOL-FYZYNONXSA-N
|
| InChi Code |
InChI=1S/C24H27N5O5.ClH/c1-15-12-21(30)34-20-13-17(9-10-18(15)20)28-22(31)19(8-5-11-27-23(25)26)29-24(32)33-14-16-6-3-2-4-7-16;/h2-4,6-7,9-10,12-13,19H,5,8,11,14H2,1H3,(H,28,31)(H,29,32)(H4,25,26,27);1H/t19-;/m0./s1
|
| Chemical Name |
benzyl N-[(2S)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]carbamate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9922 mL | 9.9610 mL | 19.9219 mL | |
| 5 mM | 0.3984 mL | 1.9922 mL | 3.9844 mL | |
| 10 mM | 0.1992 mL | 0.9961 mL | 1.9922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
